The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for ...

Upstream Bio filed for an initial public offering with the Securities and Exchange Commission. The Waltham, Mass., clinical-stage biotechnology company didn't say Wednesday how many shares it would ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

“Ninety-five percent of the cases present with severe asthma and sinus disease and nasal polyps. So, if you’re not looking ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Sen. JD Vance (R-Ohio), the Republican vice presidential candidate, is backtracking on whether President Trump would veto a ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Jassey, DOSinus infection symptoms and cold symptoms often appear similar, but there are some key differences that impact ...